Share |
   
   (Select the topic of your choice)

Diabetic Retinopathy News

Diabetic Retinopathy May Predict Stroke Risk
Stroke: March 2007
-Researchers at the University of Melbourne in Australia reported in the journal Stroke, that patients with diabetic retinopathy appear to have an increased risk of developing a stroke. They identified that the same factors causing damage to blood vessels in the Retina and causing diabetic retinopathy, also can be associated with an increased risk of stroke suggesting that patients with diabetic retinopathy also should be carefully monitored for the possibility of developing strokes.

Nepafenac Eye Drops Could Reduce Diabetic Eye Damage
Diabetes: February 2007
-A non steroidal anti-inflammatory eye drop commonly used after cataract surgery called Nepafenac has been reported in the journal Diabetes to reduce microvascular damage in the retina of rats that is similar to the damage found in diabetic retinopathy. Researchers are hopeful that this could offer a benefit to patients with diabetes.

Lucentis and Diabetic Retinopathy
American Journal of Ophthalmology: December 2006
-Researchers from the Johns Hopkins University-Wilmer Eye Institute reported results indicating the Lucentis Injections are useful as a treatment for diabetic retinopathy based on the findings in a small clinical trial in which there was significant visual improvement in people with early stages of the diabetic retinopathy that received Lucentis Injections. In particular, those patients with thickening of their Macula experienced dramatic improvement within a week after treatment, which actually continued to improve with repeated therapeutic injections. Similar results have been reported with Avastin Injections.

Avastin and Diabetic Retinopathy
American Journal of Ophthalmology: October 2006
-Research reported in the American Journal of Ophthalmology, indicates that Avastin Injections eliminated neovascularization, or abnormal blood vessel growth, that was associated with vision loss in patients with proliferative diabetic retinopathy. Proliferative diabetic retinopathy can lead to vitreous hemorrhage and retinal detachment so achieving regression of the new blood vessel growth is a highly positive finding.

Avandia, Avandamet & Avandaryl May Cause Diabetic Macular Edema
U.S. Food and Drug Administration Warning Letter-January 2006
-The FDA warned patients, physicians and GlaxoSmithKline the manufacturer of the compound rosiglitazone, contained in Avandia, Avandamet and Avandaryl, that these drugs used to treat diabetes could cause or worsen swelling of the retina in the Macula or diabetic macular edema. additional labeling about the risk of potential development of internal eye swelling known as diabetic macular edema. Symptoms of diabetic macular edema include blurry vision, decreased ability to adapt to the dark, and decreased color sensitivity.

Diabetes and Dry Eyes
American Journal of Ophthalmology: March 2005
-A study reported in the American Journal of Ophthalmology indicated that patients with diabetes are more likely to have dry eye symptoms suggesting that inadequate blood sugar control in diabetic patients appears to be associated with development of dry eye. The study found that 20.6 percent of diabetic patients needed lubricating eye drops, compared with 13.8 percent of non-diabetic patients. This increased even further among those patients with poor blood sugar control.

Corticosteroid Injections for Diabetic Retinopathy
British Journal of Ophthalmology: March 2005
-Researchers at the University of Heidelberg reported that the intravitreal injection of the corticosteroid Triamcinolone Acetonide effected significant improvement in patients with retinal swelling or diabetic macular edema. More than two thirds of those patients treated achieved an improvement of two or more lines of Snellin Visual Acuity and the effects lasted for as long as seven months after treatment. This suggests an important role of therapeutic injections of the anti-inflammatory drug Triamcinolone Acetonide in treating diabetic retinopathy.


< Back


©2011 The Medical Management Services Group

updated 2/23/11